We're going to go right into the boosters. We're talking third, fourth, fifth boosters.

We've been covering this. But let's look at one of the voters. We have Dr. Paul

Affitt. He's on the Verbat committee. He's voted for vaccines. He's voted for

the boosters. But let's listen to what he had to say about the recent boosters

for the Omicron variant, which is the variant that is dominant right now, going

through its several variations of its variant. Here's what he had to say in

an interview recently. Normally you get the the EUA submission from the company,

which is 85 to 100 pages long. And then you get the FDA's review of all those

data. It really, really is hard. And I mean, it is a very thorough review. Not

here. Here was 22 pages from the FDA, which included a half a page on Pfizer's

data and a half a page on Moderna's data. You could get that from the press release.

In fact, there was no more detail, frankly, than the press release. So I just

thought the question we're being asked is in the end, always, is do the benefits

that weigh the risk, even though the risks are generally small and sometimes unknown,

that's always the question. Do the benefits of this vaccine outweigh the

rest? I didn't see the benefits. I was surprised, actually, frankly, that of the

21 voting members 19 voted yes, because I just didn't see the evidence for

that. And we'll see how this plays out. I mean, this was something that I think

they, the that was that was desired by this administration. I could be wrong.

But the way that this, the other thing that was odd about this meeting was that we're

an advisory committee. We're being asked for our advice. So normally what happens

is they just presented data. Here's the data, but your advice. And people can ignore

...